Kunzhe Dong1, Jian Shen1,2, Xiangqin He1,3, Guoqing Hu1, Liang Wang1,4, Islam Osman1, Kristopher M Bunting1, Rachael Dixon-Melvin1, Zeqi Zheng4, Hongbo Xin5, Meixiang Xiang2, Almira Vazdarjanova1, David J R Fulton1,6, Jiliang Zhou1. 1. Department of Pharmacology and Toxicology (K.D., J.S., X.H., G.H., L.W., I.O., K.M.B., R.D.-M., A.V., D.J.R.F., J.Z.), Medical College of Georgia, Augusta University. 2. Department of Cardiology, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China (J.S., M.X.). 3. The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine (H.X.), Nanchang University, Jiangxi, China. 4. Department of Cardiology, The First Affiliated Hospital of Nanchang University, Jiangxi, China (L.W., Z.Z.). 5. School of Life Sciences (H.X.), Nanchang University, Jiangxi, China. 6. Vascular Biology Center (D.J.R.F.), Medical College of Georgia, Augusta University.
Abstract
BACKGROUND: Vascular homeostasis is maintained by the differentiated phenotype of vascular smooth muscle cells (VSMCs). The landscape of protein coding genes comprising the transcriptome of differentiated VSMCs has been intensively investigated but many gaps remain including the emerging roles of noncoding genes. METHODS: We reanalyzed large-scale, publicly available bulk and single-cell RNA sequencing datasets from multiple tissues and cell types to identify VSMC-enriched long noncoding RNAs. The in vivo expression pattern of a novel smooth muscle cell (SMC)-expressed long noncoding RNA, Carmn (cardiac mesoderm enhancer-associated noncoding RNA), was investigated using a novel Carmn green fluorescent protein knock-in reporter mouse model. Bioinformatics and quantitative real-time polymerase chain reaction analysis were used to assess CARMN expression changes during VSMC phenotypic modulation in human and murine vascular disease models. In vitro, functional assays were performed by knocking down CARMN with antisense oligonucleotides and overexpressing Carmn by adenovirus in human coronary artery SMCs. Carotid artery injury was performed in SMC-specific Carmn knockout mice to assess neointima formation and the therapeutic potential of reversing CARMN loss was tested in a rat carotid artery balloon injury model. The molecular mechanisms underlying CARMN function were investigated using RNA pull-down, RNA immunoprecipitation, and luciferase reporter assays. RESULTS: We identified CARMN, which was initially annotated as the host gene of the MIR143/145 cluster and recently reported to play a role in cardiac differentiation, as a highly abundant and conserved, SMC-specific long noncoding RNA. Analysis of the Carmn GFP knock-in mouse model confirmed that Carmn is transiently expressed in embryonic cardiomyocytes and thereafter becomes restricted to SMCs. We also found that Carmn is transcribed independently of Mir143/145. CARMN expression is dramatically decreased by vascular disease in humans and murine models and regulates the contractile phenotype of VSMCs in vitro. In vivo, SMC-specific deletion of Carmn significantly exacerbated, whereas overexpression of Carmn markedly attenuated, injury-induced neointima formation in mouse and rat, respectively. Mechanistically, we found that Carmn physically binds to the key transcriptional cofactor myocardin, facilitating its activity and thereby maintaining the contractile phenotype of VSMCs. CONCLUSIONS: CARMN is an evolutionarily conserved SMC-specific long noncoding RNA with a previously unappreciated role in maintaining the contractile phenotype of VSMCs and is the first noncoding RNA discovered to interact with myocardin.
BACKGROUND: Vascular homeostasis is maintained by the differentiated phenotype of vascular smooth muscle cells (VSMCs). The landscape of protein coding genes comprising the transcriptome of differentiated VSMCs has been intensively investigated but many gaps remain including the emerging roles of noncoding genes. METHODS: We reanalyzed large-scale, publicly available bulk and single-cell RNA sequencing datasets from multiple tissues and cell types to identify VSMC-enriched long noncoding RNAs. The in vivo expression pattern of a novel smooth muscle cell (SMC)-expressed long noncoding RNA, Carmn (cardiac mesoderm enhancer-associated noncoding RNA), was investigated using a novel Carmn green fluorescent protein knock-in reporter mouse model. Bioinformatics and quantitative real-time polymerase chain reaction analysis were used to assess CARMN expression changes during VSMC phenotypic modulation in human and murine vascular disease models. In vitro, functional assays were performed by knocking down CARMN with antisense oligonucleotides and overexpressing Carmn by adenovirus in human coronary artery SMCs. Carotid artery injury was performed in SMC-specific Carmn knockout mice to assess neointima formation and the therapeutic potential of reversing CARMN loss was tested in a rat carotid artery balloon injury model. The molecular mechanisms underlying CARMN function were investigated using RNA pull-down, RNA immunoprecipitation, and luciferase reporter assays. RESULTS: We identified CARMN, which was initially annotated as the host gene of the MIR143/145 cluster and recently reported to play a role in cardiac differentiation, as a highly abundant and conserved, SMC-specific long noncoding RNA. Analysis of the Carmn GFP knock-in mouse model confirmed that Carmn is transiently expressed in embryonic cardiomyocytes and thereafter becomes restricted to SMCs. We also found that Carmn is transcribed independently of Mir143/145. CARMN expression is dramatically decreased by vascular disease in humans and murine models and regulates the contractile phenotype of VSMCs in vitro. In vivo, SMC-specific deletion of Carmn significantly exacerbated, whereas overexpression of Carmn markedly attenuated, injury-induced neointima formation in mouse and rat, respectively. Mechanistically, we found that Carmn physically binds to the key transcriptional cofactor myocardin, facilitating its activity and thereby maintaining the contractile phenotype of VSMCs. CONCLUSIONS: CARMN is an evolutionarily conserved SMC-specific long noncoding RNA with a previously unappreciated role in maintaining the contractile phenotype of VSMCs and is the first noncoding RNA discovered to interact with myocardin.
Entities:
Keywords:
RNA, long noncoding; myocytes, smooth muscle; vascular diseases
Authors: J Solway; J Seltzer; F F Samaha; S Kim; L E Alger; Q Niu; E E Morrisey; H S Ip; M S Parmacek Journal: J Biol Chem Date: 1995-06-02 Impact factor: 5.157
Authors: Thomas Boettger; Nadine Beetz; Sawa Kostin; Johanna Schneider; Marcus Krüger; Lutz Hein; Thomas Braun Journal: J Clin Invest Date: 2009-08-17 Impact factor: 14.808
Authors: Huize Pan; Chenyi Xue; Benjamin J Auerbach; Mingyao Li; Muredach P Reilly; Jiaxin Fan; Alexander C Bashore; Jian Cui; Dina Y Yang; Sarah B Trignano; Wen Liu; Jianting Shi; Chinyere O Ihuegbu; Erin C Bush; Jeremy Worley; Lukas Vlahos; Pasquale Laise; Robert A Solomon; Edward S Connolly; Andrea Califano; Peter A Sims; Hanrui Zhang Journal: Circulation Date: 2020-09-23 Impact factor: 29.690